Nasdaq
$3.86▲ 1.98%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $38.3MShares out 9.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.28After-hours26.09.29 05:018-KKey event#●●●#●●●#●●●
SCYNEXIS INCBullish
SCYNEXIS has entered into a contract with BARDA for up to $214 million in non-dilutive funding to support the development of its antifungal candidate, SCY-247. The initial base period provides approximately $18.5 million to advance oral and intravenous SCY-247 into a Phase 2 study for invasive candidiasis. The company confirmed that its existing operating plan and projected cash runway into 2029 remain unchanged.…more
$3.86+1.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 05:024Ownership
SCYNEXIS INC
Burke Steven Keith, an executive at SCYNEXIS INC, reported a change in beneficial ownership of securities as of September 18, 2026. This filing is a Form 4 report submitted to the SEC regarding insider equity transactions.…more
$3.86+1.98%vs prev closeView filingShare - 9.22After-hours26.09.23 05:013Ownership
SCYNEXIS INC
Steven Burke has filed a limited power of attorney authorizing designated individuals to act on his behalf for SEC Section 16 reporting obligations regarding Scynexis, Inc. securities. This is an administrative filing related to insider transaction reporting and does not impact the company's financial or operational status.…more
$3.86+1.98%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:00#●●●#●●●
SCYNEXIS Completes Phase 1 Study of Antifungal Candidate SCY-247
SCYNEXIS has successfully completed the Phase 1 clinical trial for its intravenous antifungal candidate, SCY-247. The company plans to initiate Phase 2 development in 2027, supported by up to $214 million in non-dilutive funding from BARDA.…more
$3.86+1.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 3d agoAfter-hours26.10.22 05:05
●●●●●●●● ●●●●● ●●●●●●
SCYNEXIS will feature its second-generation antifungal candidate, SCY-247, in a pipeline presentation at the upcoming IDWeek conference. The presentation will highlight the drug's potential to treat drug-resistant fungal infections.…more
$3.86+1.98%vs prev close - 10.6Pre-market26.10.06 20:31
●●●●●●●● ●●●●● ●●●●●●
SCYNEXIS has successfully completed the Phase 1 study for its ADPKD treatment candidate, SCY-770, demonstrating a favorable safety profile. The company remains on track to initiate a Phase 2 proof-of-concept study in the fourth quarter of 2026.…more
$3.86+1.98%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report